Brazilian Journal of Implantology and Health Sciences · Sep 7, 2026
Olfactory Dysfunctions as a Functional Biomarker in Parkinson's Disease and Alzheimer's Disease: A Scoping Review
By Lopes TS, Lima MIA, Morais SDA et al.
INTRODUCTION: Neurodegenerative diseases, especially Parkinson's disease and Alzheimer's disease, represent a major public health challenge because of their high prevalence, progressive nature, and significant functional impact. The diagnosis of these conditions remains predominantly clinical and is often made at advanced stages, reinforcing the need for early biomarkers capable of identifying individuals at risk in the preclinical and prodromal phases. In this context, olfactory dysfunctions, such as hyposmia and anosmia, have been investigated as possible early clinical markers of the neurodegenerative process. OBJECTIVE: This study aimed to map and synthesize the scientific evidence on the use of olfactory tests as early markers of neurodegenerative diseases, with an emphasis on Parkinson's disease and Alzheimer's disease. METHODS: This is a scoping review conducted in accordance with the methodological recommendations of the Joanna Briggs Institute and structured according to the PCC model. The search was conducted in the PubMed/MEDLINE database, covering the period from 2015 to 2025, using descriptors related to olfactory dysfunction, early diagnosis, and neurodegenerative diseases. Initially, 61 studies were identified. After filters were applied and the full texts were read, 12 articles met the eligibility criteria and constituted the final sample. CONCLUSIONS: It is concluded that olfactory dysfunction constitutes a promising and consistent functional biomarker in the literature for the early detection of neurodegenerative diseases. Because it is a noninvasive, low-cost method that can be applied on a large scale, its incorporation into clinical protocols may contribute to earlier diagnosis, risk stratification, and more timely therapeutic planning.
doi.org/10.36557/2674-8169.2026v8n9p339-354Open accessBiomarkers